Molina-Cuadrado, EmilioMateo-Carrrasco, HectorCollado, AntonioMartin, Marta Casado2025-01-072025-01-072018-05-012047-9956https://hdl.handle.net/10668/24955Objectives Anaemia is the most common side effect associated with ribavirin (RBV). This study intended to assess its incidence and determine its predictive factors in patients with hepatitis C virus on RBV plus direct-acting antiviral agents (DAAs).Methods A retrospective study of patients receiving RBV+DAA was conducted. Serum haemoglobin (Hb) was determined at baseline and monitored 4weekly. Anaemia was defined as a single occurrence of HbenRibavirinDirect-acting antiviralAnaemiaPredictorHepatitis CPeginterferonTelaprevirTherapyCombinationAlpha-2aresearch article31157007open access10.1136/ejhpharm-2017-0012772047-9964https://europepmc.org/articles/pmc6452397?pdf=render431400800006